Halozyme Therapeutics, Inc. (NASDAQ:HALO) was upgraded by stock analysts at BidaskClub from a “buy” rating to a “strong-buy” rating in a report released on Saturday.

Other research analysts also recently issued reports about the company. Deutsche Bank AG upped their price target on Halozyme Therapeutics from $15.00 to $17.00 and gave the stock a “buy” rating in a research note on Thursday, March 30th. ValuEngine raised Halozyme Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd. Zacks Investment Research raised Halozyme Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, May 12th. BMO Capital Markets started coverage on Halozyme Therapeutics in a research note on Monday, April 17th. They set a “market perform” rating and a $14.00 price target on the stock. Finally, Barclays PLC reaffirmed an “overweight” rating and set a $16.00 price target on shares of Halozyme Therapeutics in a research note on Friday. One research analyst has rated the stock with a sell rating, four have issued a hold rating, four have given a buy rating and one has given a strong buy rating to the company. Halozyme Therapeutics has a consensus rating of “Buy” and a consensus target price of $14.68.

Analyst Recommendations for Halozyme Therapeutics (NASDAQ:HALO)

Halozyme Therapeutics (NASDAQ:HALO) traded up 0.40% during midday trading on Friday, hitting $14.89. The stock had a trading volume of 1,680,581 shares. The stock’s market capitalization is $1.92 billion. The company’s 50 day moving average price is $13.32 and its 200-day moving average price is $12.66. Halozyme Therapeutics has a 52 week low of $7.70 and a 52 week high of $15.20.

Halozyme Therapeutics (NASDAQ:HALO) last announced its earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.25) by $0.01. Halozyme Therapeutics had a negative net margin of 86.80% and a negative return on equity of 405.28%. The business had revenue of $29.60 million for the quarter, compared to the consensus estimate of $30.79 million. During the same quarter in the previous year, the company earned ($0.16) EPS. The firm’s revenue for the quarter was down 30.4% on a year-over-year basis. Equities analysts anticipate that Halozyme Therapeutics will post ($1.00) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This article was originally published by American Banking News and is the property of of American Banking News. If you are viewing this article on another publication, it was illegally stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this article can be accessed at https://www.americanbankingnews.com/2017/06/24/halozyme-therapeutics-inc-halo-lifted-to-strong-buy-at-bidaskclub.html.

A number of hedge funds and other institutional investors have recently bought and sold shares of HALO. Ameritas Investment Partners Inc. purchased a new position in Halozyme Therapeutics during the first quarter worth $122,000. Stifel Financial Corp bought a new stake in shares of Halozyme Therapeutics during the first quarter valued at approximately $187,000. Karp Capital Management Corp bought a new stake in shares of Halozyme Therapeutics during the first quarter valued at approximately $188,000. Dynamic Technology Lab Private Ltd increased its stake in shares of Halozyme Therapeutics by 75.0% in the fourth quarter. Dynamic Technology Lab Private Ltd now owns 19,589 shares of the biopharmaceutical company’s stock valued at $193,000 after buying an additional 8,396 shares during the period. Finally, Capstone Investment Advisors LLC bought a new stake in shares of Halozyme Therapeutics during the fourth quarter valued at approximately $197,000. 81.77% of the stock is currently owned by institutional investors and hedge funds.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company’s segment also includes research and development activities and product sales of Hylenex recombinant.

Receive News & Ratings for Halozyme Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.